{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T12:55:33Z","timestamp":1789390533364,"version":"build-2803163510"},"reference-count":24,"publisher":"American Diabetes Association","issue":"9","content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2013,9,1]]},"abstract":"<jats:sec><jats:title>OBJECTIVE<\/jats:title><jats:p>When oral therapy for type 2 diabetes is ineffective, adding basal insulin improves glycemic control. However, when glycated hemoglobin (HbA1c) remains elevated because of postprandial hyperglycemia, the next therapeutic step is controversial. We examined the efficacy and safety of lixisenatide in patients with HbA1c still elevated after initiation of insulin glargine.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESEARCH DESIGN AND METHODS<\/jats:title><jats:p>This double-blind, parallel-group trial enrolled patients with HbA1c 7\u201310% despite oral therapy. Insulin glargine was added and systematically titrated during a 12-week run-in, after which candidates with fasting glucose \u22647.8 mmol\/L and HbA1c 7\u20139% were randomized to lixisenatide 20 \u00b5g or placebo for 24 weeks while insulin titration continued. The primary end point was HbA1c change after randomization.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>The randomized population (n = 446) had mean diabetes duration of 9.2 years, BMI 31.8 kg\/m2, and daily glargine dosage of 44 units. HbA1c had decreased during run-in from 8.6 to 7.6%; adding lixisenatide further reduced HbA1c by 0.71 vs. 0.40% with placebo (least squares mean difference, \u20130.32%; 95% CI, \u20130.46 to \u20130.17; P &amp;lt; 0.0001). More participants attained HbA1c &amp;lt;7% with lixisenatide (56 vs. 39%; P &amp;lt; 0.0001). Lixisenatide reduced plasma glucose 2 h after a standardized breakfast (difference vs. placebo \u20133.2 mmol\/L; P &amp;lt; 0.0001) and had a favorable effect on body weight (difference vs. placebo \u20130.89 kg; P = 0.0012). Nausea, vomiting, and symptomatic hypoglycemia &amp;lt;3.3 mmol\/L were more common with lixisenatide.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>Adding lixisenatide to insulin glargine improved overall and postprandial hyperglycemia and deserves consideration as an alternative to prandial insulin for patients not reaching HbA1c goals with recently initiated basal insulin.<\/jats:p><\/jats:sec>","DOI":"10.2337\/dc12-2462","type":"journal-article","created":{"date-parts":[[2013,4,6]],"date-time":"2013-04-06T05:06:31Z","timestamp":1365224791000},"page":"2497-2503","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":213,"title":["Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled With Newly Initiated and Continuously Titrated Basal Insulin Glargine"],"prefix":"10.2337","volume":"36","author":[{"given":"Matthew C.","family":"Riddle","sequence":"first","affiliation":[{"name":"Oregon Health and Science University, Portland, Oregon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Forst","sequence":"additional","affiliation":[{"name":"Institute for Clinical Research and Development, Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronnie","family":"Aronson","sequence":"additional","affiliation":[{"name":"LMC Diabetes and Endocrinology, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leobardo","family":"Sauque-Reyna","sequence":"additional","affiliation":[{"name":"Instituto de Diabetes Obesidad y Nutrici\u00f3n Sociedad Civil, Cuernavaca, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Souhami","sequence":"additional","affiliation":[{"name":"Sanofi, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Silvestre","sequence":"additional","affiliation":[{"name":"Sanofi, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Ping","sequence":"additional","affiliation":[{"name":"Sanofi, Bridgewater, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"Rosenstock","sequence":"additional","affiliation":[{"name":"Dallas Diabetes and Endocrine Center at Medical City, Dallas at Medical City, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2013,8,13]]},"reference":[{"key":"2022031302004032600_B1","doi-asserted-by":"crossref","first-page":"3S","DOI":"10.1016\/j.amjmed.2003.12.003","article-title":"Timely initiation of basal insulin","volume":"116","author":"Riddle","year":"2004","journal-title":"Am J Med"},{"key":"2022031302004032600_B2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00125-008-1157-y","article-title":"Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes","volume":"52","author":"Nathan","year":"2009","journal-title":"Diabetologia"},{"key":"2022031302004032600_B3","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.2337\/diacare.26.11.3080","article-title":"The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients","volume":"26","author":"Riddle","year":"2003","journal-title":"Diabetes Care"},{"key":"2022031302004032600_B4","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/dmrr.733","article-title":"When basal insulin therapy in type 2 diabetes mellitus is not enough\u2014what next?","volume":"23","author":"Raccah","year":"2007","journal-title":"Diabetes Metab Res Rev"},{"key":"2022031302004032600_B5","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.diabres.2006.11.011","article-title":"Impact of fasting and postprandial glycemia on overall glycemic control in type 2 diabetes Importance of postprandial glycemia to achieve target HbA1c levels","volume":"77","author":"Woerle","year":"2007","journal-title":"Diabetes Res Clin Pract"},{"key":"2022031302004032600_B6","doi-asserted-by":"crossref","first-page":"881","DOI":"10.2337\/diacare.26.3.881","article-title":"Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c)","volume":"26","author":"Monnier","year":"2003","journal-title":"Diabetes Care"},{"key":"2022031302004032600_B7","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1111\/j.1464-5491.2009.02809.x","article-title":"Relative and absolute contributions of postprandial and fasting plasma glucose to daytime hyperglycaemia and HbA(1c) in subjects with Type 2 diabetes","volume":"26","author":"Peter","year":"2009","journal-title":"Diabet Med"},{"key":"2022031302004032600_B8","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.2337\/dc11-0632","article-title":"Contributions of basal and postprandial hyperglycemia over a wide range of A1C levels before and after treatment intensification in type 2 diabetes","volume":"34","author":"Riddle","year":"2011","journal-title":"Diabetes Care"},{"key":"2022031302004032600_B9","first-page":"S13","article-title":"Insulin therapy for management of type 2 diabetes mellitus: strategies for initiation and long-term patient adherence","volume":"111","author":"Barag","year":"2011","journal-title":"J Am Osteopath Assoc"},{"key":"2022031302004032600_B10","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1089\/dia.2009.0127","article-title":"The role of basal insulin and glucagon-like peptide-1 agonists in the therapeutic management of type 2 diabetes\u2014a comprehensive review","volume":"12","author":"Garg","year":"2010","journal-title":"Diabetes Technol Ther"},{"key":"2022031302004032600_B11","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1345\/aph.1P047","article-title":"Glucagon-like peptide-1 analog and insulin combination therapy in the management of adults with type 2 diabetes mellitus","volume":"44","author":"Tzefos","year":"2010","journal-title":"Ann Pharmacother"},{"key":"2022031302004032600_B12","doi-asserted-by":"crossref","first-page":"103","DOI":"10.7326\/0003-4819-154-2-201101180-00300","article-title":"Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial","volume":"154","author":"Buse","year":"2011","journal-title":"Ann Intern Med"},{"key":"2022031302004032600_B13","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/S0140-6736(06)69705-5","article-title":"The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes","volume":"368","author":"Drucker","year":"2006","journal-title":"Lancet"},{"key":"2022031302004032600_B14","doi-asserted-by":"crossref","first-page":"559","DOI":"10.7326\/0003-4819-143-8-200510180-00006","article-title":"Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial","volume":"143","author":"Heine","year":"2005","journal-title":"Ann Intern Med"},{"key":"2022031302004032600_B15","doi-asserted-by":"crossref","first-page":"67","DOI":"10.2147\/CE.S15525","article-title":"Lixisenatide: evidence for its potential use in the treatment of type 2 diabetes","volume":"6","author":"Barnett","year":"2011","journal-title":"Core Evid"},{"key":"2022031302004032600_B16","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1111\/j.1464-5491.2010.03020.x","article-title":"Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial","volume":"27","author":"Ratner","year":"2010","journal-title":"Diabet Med"},{"key":"2022031302004032600_B17","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.regpep.2010.05.008","article-title":"Pharmacological profile of lixisenatide: A new GLP-1 receptor agonist for the treatment of type 2 diabetes","volume":"164","author":"Werner","year":"2010","journal-title":"Regul Pept"},{"key":"2022031302004032600_B18"},{"key":"2022031302004032600_B19","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1111\/j.1463-1326.2011.01459.x","article-title":"Effects of initiation and titration of a single pre-prandial dose of insulin glulisine while continuing titrated insulin glargine in type 2 diabetes: a 6-month \u2018proof-of-concept\u2019 study","volume":"13","author":"Owens","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"2022031302004032600_B20","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1111\/j.1463-1326.2008.00967.x","article-title":"Introducing a simplified approach to insulin therapy in type 2 diabetes: a comparison of two single-dose regimens of insulin glulisine plus insulin glargine and oral antidiabetic drugs","volume":"10","author":"Lankisch","year":"2008","journal-title":"Diabetes Obes Metab"},{"key":"2022031302004032600_B21","doi-asserted-by":"crossref","first-page":"727","DOI":"10.4158\/EP10367.OR","article-title":"Comparison of 2 intensification regimens with rapid-acting insulin aspart in type 2 diabetes mellitus inadequately controlled by once-daily insulin detemir and oral antidiabetes drugs: the step-wise randomized study","volume":"17","author":"Meneghini","year":"2011","journal-title":"Endocr Pract"},{"key":"2022031302004032600_B22","doi-asserted-by":"crossref","first-page":"395","DOI":"10.4158\/EP10323.OR","article-title":"A stepwise approach to insulin therapy in patients with type 2 diabetes mellitus and basal insulin treatment failure","volume":"17","author":"Davidson","year":"2011","journal-title":"Endocr Pract"},{"key":"2022031302004032600_B23","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.2337\/dc11-1935","article-title":"Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono)","volume":"35","author":"Fonseca","year":"2012","journal-title":"Diabetes Care"},{"key":"2022031302004032600_B24","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1463-1326.2011.01507.x","article-title":"Treating diabetes today: a matter of selectivity of sulphonylureas","volume":"14","author":"Seino","year":"2012","journal-title":"Diabetes Obes Metab"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/36\/9\/2497\/619490\/2497.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/36\/9\/2497\/619490\/2497.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T11:54:05Z","timestamp":1715169245000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/36\/9\/2497\/37933\/Adding-Once-Daily-Lixisenatide-for-Type-2-Diabetes"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8,13]]},"references-count":24,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2013,8,13]]},"published-print":{"date-parts":[[2013,9,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc12-2462","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,13]]}}}